Savara Inc. Engages Investors at Significant Healthcare Conferences
Savara Inc. (NASDAQ: SVRA) is excited to announce that its management team will be actively participating in two important healthcare conferences soon. These events are vital for engaging stakeholders and discussing advances in treatments for rare respiratory diseases.
Upcoming Conferences and Participation Details
At the upcoming conferences, Savara's management will host one-on-one meetings and participate in notable fireside chats. This is an opportunity for the team to connect with investors and share insights about the company's exciting pipeline and ongoing developments.
Piper Sandler 37th Annual Healthcare Conference
This conference is set for December 2, 2025, at approximately 2:30 PM ET. Savara's presence will spotlight its ongoing commitment to addressing rare respiratory diseases through innovative biotechnology.
Evercore ISI 8th Annual Healthcare Conference
Following the Piper Sandler event, Savara will join the Evercore ISI conference on December 4, 2025, at 10:00 AM ET. This provides another platform for the company to communicate its strategic initiatives and meet with various investors.
Webcast Access and Company Information
For those interested in following along, live webcasts of these events will be available in the "Events & Presentations" section on Savara's official website. Additionally, the webcasts will be archived for a period of 90 days, allowing followers to catch up on any missed discussions.
About Savara Inc.
Savara is at the forefront of developing treatments for rare respiratory diseases. The company's lead program, MOLBREEVI, focuses on autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and is currently in Phase 3 trials. MOLBREEVI utilizes a proprietary investigational nebulizer system designed to facilitate efficient delivery of the treatment.
The Expertise Behind Savara
The dedicated team at Savara boasts extensive experience in the field of pulmonary medicine. This collective expertise is crucial for identifying unmet medical needs and advancing treatments from development to commercial stages.
Contact Information for Inquiries
Media and investor relations inquiries can be directed to Temre Johnson, the Executive Director of Corporate Affairs at Savara Inc. For further information or questions, reach out via email at ir@savarapharma.com.
Frequently Asked Questions
What are the key dates for Savara's upcoming conferences?
Savara is participating in two key conferences: the Piper Sandler Conference on December 2, 2025, and the Evercore ISI Conference on December 4, 2025.
How can one access the webcasts of the conferences?
The live webcasts and subsequent replays can be accessed through the "Events & Presentations" section on Savara's official website and will be available for 90 days.
What is MOLBREEVI?
MOLBREEVI is Savara's lead program, aimed at treating autoimmune pulmonary alveolar proteinosis and is currently in Phase 3 development.
Who should be contacted for investor relations?
Investors can contact Temre Johnson, the Executive Director of Corporate Affairs, at ir@savarapharma.com for inquiries related to investor relations.
What is Savara’s focus as a company?
Savara Inc. specializes in developing innovative treatments for rare respiratory diseases, emphasizing patient-care solutions and addressing unmet medical needs.